Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
To The Editor: Dr Chen and colleagues1 reported that recent long-term HRT was associated
with an increased risk of breast cancer, and that such HRT was related particularly
to lobular tumors.
Table 1 of their article shows that 30.8% of the cases and 32.4% of
the controls had histories of surgical menopause, and for these women Table
3 shows that oral HRT within the past 5 years was associated with a significant
increase in the risk of breast cancer across durations of HRT ranging from
less than 18 months (odds ratio [OR], 1.75) to more than 57 months (OR, 2.45; P = .003 for trend). For women with histories of natural
menopause, however, Table 3 shows less evidence of an increase in the risk
of breast cancer across durations of oral HRT ranging from less than 18 months
(OR, 0.92) to more than 57 months (OR, 1.41; P =
.10 for trend).
Stadel BV. Hormone Replacement Therapy and Risk of Breast Cancer. JAMA. 2002;287(18):2360–2361. doi:10.1001/jama.287.18.2359
Customize your JAMA Network experience by selecting one or more topics from the list below.